Skip to main content
Premium Trial:

Request an Annual Quote

MDx Platform Firm InSilixa Completes $13M Financing Round

NEW YORK (GenomeWeb) – New molecular diagnostics platform firm InSilixa has completed a $13 million private financing round.

The funding from Silicon Valley VC firm PointGuard Ventures and private investment group Morningside will support InSilixa's development of MDx platforms based on integrated circuit manufacturing technologies, in particular complementary metal-oxide semiconductor (CMOS) processes, PointGuard and Morningside said. InSilixa's products, including its CMOS biochips, are designed to be cost-effective, mass-deployable, and disposable, while also offering superior clinical performance, specificity, and parallelism.

The company's technology is licensed from California Institute of Technology, the University of Texas, Austin, and Stanford University.

Without providing details, PointGuard and Morningside said that InSilixa's first products will focus on highly multiplexed genomic tests for the point-of-care and the near-patient settings for infectious disease detection. The company is developing a platform-based architecture, and its point-of-care systems are able to rapidly identify the infecting pathogen in clinical samples, while also verifying the absence or presence of genetic mutations that cause antibiotic resistance, the investors said.

InSilixa is based in Sunnyvale, Calif., and was founded in 2012.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.